



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/762,566-Conf. #3220
				Filing Date	January 23, 2004
				First Named Inventor	Richard Franklin
				Art Unit	1614
				Examiner Name	A. R. Hughes
Sheet	1	of	5	Attorney Docket Number	20342/1202529-US1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	AA*	US-3,983,119	09-28-1976	Beverung, Jr. et al.	
	AB*	US-3,983,120	09-28-1976	Beverung et al.	
	AC*	US-3,988,340	10-26-1976	Partyka et al.	
	AD*	US-4,048,168	09-13-1977	Yamamoto et al.	
	AE*	US-4,146,718	03-27-1979	Jenks et al.	
	AF*	US-4,179,560	12-18-1979	Yamamoto et al.	
	AG*	US-4,202,974	05-13-1980	Yamamoto et al.	
	AH*	US-4,208,521	06-17-1980	Crenshaw et al.	
	AI*	US-4,357,330	11-02-1982	Fleming, Jr. et al.	
	AJ*	US-4,444,777	04-24-1984	Fleming, Jr. et al.	
	AK*	US-4,837,239	06-06-1989	Benjamin et al.	
	AL*	US-5,801,245	09-01-1998	Lang	
	AM*	US-5,391,737	02-21-1995	Reiter et al.	
	AN*	US-6,388,073	05-14-2002	Lang et al.	
	AO*	US-6,548,490	04-15-2003	Doherty, Jr. et al.	
	AP*	US-20030114673-A1	06-19-2003	Lang	
	AQ*	US-20040209907-A1	10-21-2004	Franklin	
	AR*	US-2,862,966	12-02-1958	Surrey	
	AS*	US-3,928,476	12-23-1975	Shimada et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	MM-DD-YYYY			
	BA	EP-0205280	12-17-1986	Pfizer Ltd et al.		
	BB	EP-0054180	06-23-1982	Hoffman-La Roche AG		✓
	BC	EP-0046267	02-24-1982	Hoffman-La Roche AG		✓
	BD	WO 2006/017822	02-16-2006	Shire Holdings AG		
	BE	DE-2832138-A1	02-08-1979	F. Hoffman-La Roche & Co		✓
	BF	AT-A2732004	08-25-2005	AOP Orphan Pharmaceuticals AG		✓
	BG	DE-19935209	02-08-2001	Truss, et al.		✓

Examiner Signature	Date Considered
-----------------------	--------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO <h1>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h1> <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/762,566-Conf. #3220
				Filing Date	January 23, 2004
				First Named Inventor	Richard Franklin
				Art Unit	1614
				Examiner Name	A. R. Hughes
				Attorney Docket Number	20342/1202529-US1
Sheet	2	of	5		

[illegible]

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T
		Country Code ³ -Number ⁴ -Kind Code ⁵ (<i>if known</i>)	MM-DD-YYYY			
	BH	EU-0546697-A1	06-16-1993	American Telephone and Telegraph Co		
	BI	EU-994114-A2	04-19-2000	Roberts Laboratories Inc.		
	BJ	EU-0046267	02-24-1982	F. Hoffman-La Roche & Co.		✓
	BK	JP-01258658	10-16-1989	Nihon Nohyaku Co Ltd		✓
	BL	JP-47-19261	06-02-1972	Fujisawa Yakuhin Kogyo Kabushiki Kaisha		
	BM	WO-9428902	12-22-1994	Pfizer Inc.		
	BN	WO-9616644	06-06-1996	Pfizer Inc.		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/762,566-Conf. #3220
				Filing Date	January 23, 2004
				First Named Inventor	Richard Franklin
				Art Unit	1614
				Examiner Name	A. R. Hughes
				Attorney Docket Number	20342/1202529-US1
Sheet	3	of	5		

[illegible]

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear
		Country Code ² -Number ⁴ -Kind Code ⁵ (if known)	MM-DD-YYYY		
	BO	WO-9810765	03-19-1998	The Board of Trustees of the Leland Stanford Junior University	
	BP	WO-0140196 A1	06-07-2001	Roberts Laboratories Inc.	
	BQ	WO-02008228	01-31-2002	Shire US Inc.	
	BR	WO-2004063172	07-29-2004	Chemisch Pharmazeu Tisches Lab	
	BS	WO-2004064841 A1	08-05-2004	Shire Holding AG	
	BT	WO-2005025570 A1	03-24-2005	Diamedica Inc.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>			Complete if Known		
			Application Number	10/762,566-Conf. #3220	
			Filing Date	January 23, 2004	
			First Named Inventor	Richard Franklin	
			Art Unit	1614	
			Examiner Name	A. R. Hughes	
Sheet	4	of	5	Attorney Docket Number	20342/1202529-US1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CA	Agrylin (anagrelide hydrochloride); Product Monograph; Roberts Pharmaceuticals Corp.; 1997.	
	CB	Blood; Journal of the American Society of Hematology; W. R. Saunders Company; vol. 94; No. 10; Supplement 1 (Part 1 of 2); Nov. 15, 1999; p. 701a.	
	CC	KIENZLE et al., "1,5-Dihydroimidazoquinazolinones as blood platelet aggregation inhibitors," Eur. J. Med. Chem., 1982, 17:547-556	
	CD	Food and Drug Administration Citizen Petition No. 2004P-0365 on behalf of Shire US, Inc., dated August 13, 2004	
	CE	JONES et al., "Inhibitors of cyclic AMP phosphodiesterase. 1. Analogues of cilostamide and anagrelide," J. Med. Chem., 1987, 30:295-303	
	CF	KIENZLE et al., "Die Synthese von 2,3,4,5-1 H-Tetrahydroimidazo [2,1-b]chinazolin-2,5-dionen und analogen 2,3,4,5-1 H-Tetrahydroimidazo [1,2-a]thieno[2,3-d](bzw. [3,2-d])-pyrimidin-2,5-dionen", Helv. Chim. Acta, Vol.66, Fasc. 1 (1983)- Nr.15	
	CG	International Search Report for PCT/US05/28086 mailed June 14, 2006.	
	CH	RAFII S. ET AL. "In Response: - Is the platelet lowering activity of anagrelide mediated by its major metabolite 2-amino-5, 6-dichloro-3, 4-dihydroquinazoline (RL603)?" Experimental Hematology (Charlottesville). Vol. 30, No. 7, pg. 626-627 (2002).	
	CI	BELL, Andrew S., et al. "7-Heteroaryl-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-2(1H)-one Derivatives with Cardiac Stimulant Activity," Journal of Medicinal Chemistry, 1989, Vol. 32, No. 9, pgs. 2042-2049 (8 pages).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/762,566-Conf. #3220
				Filing Date	January 23, 2004
				First Named Inventor	Richard Franklin
				Art Unit	1614
				Examiner Name	A. R. Hughes
Sheet	5	of	5	Attorney Docket Number	20342/1202529-US1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CK	Imidazo[2,1-b]quinazolin-2(3H)-one, 1,5-dihydro-3,3-dimethyl-, monohydrochloride (9CI), as referenced in European Journal of Medicinal Chemistry (1982), 17(6), 547-56 (1 page).	
	CL	Imidazo[2,1-b]quinazolin-2(3H)-one, 1,5-dihydro-3,3,6-trimethyl-, monohydrochloride (9CI), as referenced in European Journal of Medicinal Chemistry (1982), 17(6), 547-56 (1 page).	
	CM	Imidazo[2,1-b]quinazolin-2(3H)-one, 1,5-dihydro-3,3,6-trimethyl-, as supplied by Chemstep, France. Catalog Publication Date 06/19/2007 (1 page).	
	CN	Imidazo[2,1-b]quinazolin-2(3H)-one, 1,5-dihydro-3,3-dimethyl-, as supplied by Chemstep, France. Catalog Publication Date 06/19/2007 (1 page).	
	CP	A copy of a signed Declaration pursuant to 37 C.F.R. §1.132 by Dr. Richard Franklin submitted in U.S. Patent Application Serial No. 10/762,566 on September 19, 2007 and Exhibit 1 to the Declaration (the curriculum vitae for Dr. Richard Franklin), 8 pgs.	
	CQ	COHEN-SOLAL et al., Thromb. Haemost. 1997, 78:37-41, p. 18, 131 of 5096 and p. 27, 19 of 3796	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.